From Clues to Care: Improving Recognition and Treatment of Alpha-Mannosidosis

To participate in this activity, please:

Log in Sign Up

Alpha‑mannosidosis (AM) is a rare, progressive lysosomal disorder with a broad and heterogeneous clinical phenotype that can evolve across the lifespan. Drawing on the 2024 Global Delphi Consensus Recommendations and other recent evidence, this activity focuses on practical, clinician‑oriented strategies for baseline and longitudinal assessment, use of enzyme replacement therapy and hematopoietic stem cell transplantation, monitoring treatment response and disease progression, and the coordination of interprofessional, multidisciplinary care essential for patient management.

This content is also available as a podcast.  You may listen here.

Course Credit:

0.75 AAPA Category I CME Credit
0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.50 Pharmacology Hours

Dates:

Opens: 2026-03-12
Closes: 2027-03-12

Target Audience:

National audience of medical geneticists, metabolic disease specialists, pediatricians, physician associates, nurse practitioners, nurses, genetic counselors, and pharmacists who care for patients with lysosomal disorders.

This activity is supported by an educational grant from Chiesi USA.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 hours AAPA Category 1 CME credits. Approval is valid until March 12, 2027. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours, including 0.5 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Austin Ulrich, PharmD, BCACP (Medical Writer)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Laura D. Buch, MSPAS, PA-C headshot

    Laura D. Buch, MSPAS, PA-C

    Genetics Physician Assistant
    Greenwood Genetic Center
    Greenville, South Carolina

  • Barbara K. Burton, MD headshot

    Barbara K. Burton, MD

    Professor of Pediatrics
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois

Learning Objectives

  • Identify the characteristics and clinical presentation of alpha-mannosidosis that should prompt a referral to a specialist
  • Develop patient-specific ERT treatment regimens that align with current best practices to achieve optimal patient outcomes
  • Apply recommended strategies for incorporating HSCT, supportive care, and integrated team-based care for patients with alpha-mannosidosis

Faculty Disclosures

Laura D. Buch, MSPAS, PA-C

Advisory Board: Amicus

Speakers Bureau: Chiesi, Sanofi


Barbara K. Burton, MD

Consultant: Alltrna, Alexion, Applied Therapeutics, Denali, Moderna, Takeda, Uniqure, Ulatragenyx

Speakers Bureau: Alexion, BioMarin